title: Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia.
authors.forename: N
authors.initials: N
authors.lastname: Widmer
authors.forename: V
authors.initials: V
authors.lastname: Gotta
authors.forename: A
authors.initials: A
authors.lastname: Haouala
authors.forename: L A
authors.initials: LA
authors.lastname: Decosterd
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001774:Blood Chemical Analysis / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood* / Q000378:metabolism; D008991:Monitoring, Physiologic / Q000379:methods; D009994:Osmolar Concentration; D010349:Patient Compliance; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases